All In Biotech

Drug Trial Radar · NCT06719310

Phase Ib/IIa Clinical Study of ACC017 Tablets

A Phase Ib/IIa, Randomized, Double Blinded, Perallel, Dosing Ranging, Placebo Controled and Proof of Concept Clinical Trial to Evaluate the Safety, Tolerability, PK and Antiviral Effect of ACC017 Tablet as Monotherapy/Combination With NRTI in Treatment naïve HIV-infected Adults

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Aug 28, 2024

Primary completion

Apr 28, 2025

Study completion Apr 28, 2025

Sponsor

Sponsor type
Industry
Collaborators
Chengdu Aidea Pharmaceutical Technology Co., Ltd
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase Ib/IIa, randomized, double-blind, parallel, dose ranging, placebo-controlled 'proof of concept' study is designed to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of ACC017 monotherapy and combined with FTC/TAF by sequency versus placebo in treatment-naïve HIV-1 infected adults. This study includes two stages, stage one is a single dose escalation, and all subjects will be co-administrated with FTC/TAF at 200 mg/25 mg on stage two. The study consists of a screening visit, baseline period, monotherapy period, and combination therapy period. Total 36 subjects will be randomized in a 5:1 ratio to receive one of three doses of ACC017 or placebo lasting for 10 days for monotherapy followed by 18 days for combination therapy.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • ACC017+FTC/TAFDrug

    ACC017+FTC/TAF

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AETime frame: Day 1- Day 11
  2. HIV-1 RNA viral load change from baselineTime frame: Day 11
  3. Proportion of patients with HIV-1 RNA viral load <50 copies/mLTime frame: Day 29
  4. Pharmacokinetics parameter: Cτ,ssTime frame: Day 10, Day 29
  5. Pharmacokinetics parameter: Cmin,ssTime frame: Day 10
  6. Pharmacokinetics parameter: Cmax,ssTime frame: Day 10
  7. Pharmacokinetics parameter: AUC0-τ,ssTime frame: Day 1- Day 10
  8. Pharmacokinetics parameter: Tmax,ssTime frame: Day 1-Day 10
  9. Pharmacokinetics parameter: MRT0-τ,ssTime frame: Day 1-Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.